// App-Quantinova.ai

528 : Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).

Researchers

Presenter

  • Mafalda Oliveira

Principal Investigators

  • Rodrigo Dienstmann

  • Meritxell Bellet

  • Jose Manuel Perez-Garcia

  • Patricia Gomez-Pardo

  • Eva Munoz-Couselo

  • Maria Vidal

  • Vanessa Ortega

  • Jesus Soberino

  • Esther Zamora

  • Cinta Hierro

  • Fiorella Ruiz

  • Paolo Nuciforo

  • Ana Vivancos

  • Javier Cortes

  • Cristina Saura

Medical Centers

  • Medical Oncology Department, Breast Cancer Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Oncology Data Science (OdySsey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Medical Oncology Department, Breast Cancer Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Medical Oncology Department, Hospital Ramon y Cajal, Madrid, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Serine/threonine-protein kinase mTOR

  • Transcription factor Maf

  • PI3K/AKT

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved